Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

Current Medical Research and Opinion

Volumn 33, Issue 4, 2017, Pages 647-655

  Landstedt Hallin, Lena ^a   Gundgaard, Jens ^b   Ericsson, Åsa ^c   Ellfors Zetterlund, Susanne ^c  

^a DANDERYD HOSPITAL   (Sweden)

^b NOVO NORDISK A S   (Denmark)

^c Novo Nordisk Scandinavia   (Sweden)

Author keywords

Basal insulin analogs; cost effectiveness; health economics; hypoglycemia; insulin degludec; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ARTICLE; BODY MASS; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; SENSITIVITY ANALYSIS; SWEDISH CITIZEN; ADULT; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMICS; MIDDLE AGED; SWEDEN;

ADULT; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SWEDEN;

EID: 85009986826     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1277194     Document Type: Article

References (49)

1. Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 2012;14:944-50
2. Haahr H, Heise T., A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014;53:787-800
3. Heise T, Korsatko S, Nosek L, et al. Steady state is reached within 2–3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes 2016;8:132-8
4. Revicki DA, Lenderking WR., Methods and issues associated with the use of quality-adjusted life-years. Expert Rev Pharmacoecon Outcomes Res 2012;12:105-14
5. Evans M, McEwan P., Clinical and cost-effectiveness of insulin degludec:from clinical trials to clinical practice. J Comp Eff Res 2015;11:1-8
6. Nathan DM,; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years:overview. Diabetes Care 2014;37:9-16
7. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ 2000;321:405-12
8. Farmer AJ, Brockbank KJ, Keech ML, et al. Incidence and costs of severe hypoglycaemia requiring attendance by the emergency medical services in South Central England. Diabet Med 2012;29:1447-50
9. Fulcher G, Singer J, Castañeda R, et al. The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes:two international surveys. J Med Econ 2014;17:751-61
10. Heller SR, Frier BM, Hersløv ML, et al. Severe hypoglycaemia in adults with insulin-treated diabetes:impact on healthcare resources. Diabet Med 2016;33:471-7
11. Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, et al. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ 2013;16:1453-61
12. Willis WD, Diago-Cabezudo JI, Madec-Hily A, Aslam A., Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes:results from a European online survey. Expert Rev Pharmacoecon Outcomes Res 2013;13:123-30
13. Brod M, Christensen T, Thomsen TL, Bushnell DM., The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
14. Brod M, Christensen T, Bushnell DM., Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function:results from a four-country survey. J Med Econ 2012;15:77-86
15. Brod M, Wolden M, Christensen T, Bushnell DM., Understanding the economic burden of nonsevere nocturnal hypoglycemic events:impact on work productivity, disease management, and resource utilization. Value Health 2013;16:1140-9
16. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events:a time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90
17. Harris SB, Khunti K, Landin-Olsson M, et al. Descriptions of health states associated with increasing severity and frequency of hypoglycemia:a patient-level perspective. Patient Prefer Adherence 2013;7:925-36
18. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract 2013;19:792-9
19. Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, et al. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med 2014;31:92-101
20. Evans M, McEwan P, Foos V., Insulin degludec early clinical experience:does the promise from the clinical trials translate into clinical practice-a case-based evaluation. J Med Econ 2015;18:96-105
21. Garber AJ., Treat-to-target trials:uses, interpretation and review of concepts. Diabetes Obes Metab 2014;16:193-205
22. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal–Bolus Type 1):a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-97
23. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal–Bolus Type 2):a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-507
24. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes:a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-71
25. Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal–Bolus Type 1):2-year results of a randomized clinical trial. Diabet Med 2013;30:1293-7
26. Ratner R, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes:a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:175-84
27. Lane WS, Bailey TS, Gerety G, et al. SWITCH 1:reduced hypoglycemia with insulin degludec (IDeg) vs. insulin glargine (IGlar), both U100, in patients with T1D at high risk of hypoglycemia:a randomized, double-blind, crossover trial. Diabetes 2016;65(Suppl 1):LB22 (Abstract LB87)
28. Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal–bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ 2015;18:56-68
29. Evans M, Wolden M, Gundgaard J, et al. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin–from the UK health care cost perspective. Diabetes Obes Metab 2014;16:366-75
30. Ericsson A, Pollock RF, Hunt B, Valentine WJ., Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. J Med Econ 2013;16:1442-52
31. Rothwell PM., External validity of randomised controlled trials:“to whom do the results of this trial apply?” Lancet 2005;365:82-93
32. Landstedt-Hallin L., Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting:an observational study. Curr Med Res Opin 2015;31:1487-93
33. JMP Statistical Software. Available at:http://www.jmp.com/en_us/offers/free-trial.html?gclid=CIymucWO3tACFY9KDQodVScAhQ last accessed 15 Nov 2016
34. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model:Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-S26
35. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27-S40
36. McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24
37. Volker, Foos, Mark, Lamotte, Phil, McEwan. Contrasting predictions of cardiovascular incidence derived from alternative risk prediction models in type 1 diabetes. PRM72, ISPOR 18th Annual European Congress, Milan, Italy, November 2015
38. Cederholm J, Eeg-Olofsson K, Eliasson B, et al. A new model for 5-year risk of cardiovascular disease in type 1 diabetes; from the Swedish National Diabetes Register (NDR). Diabet Med 2011;28:1213-20
39. Färnkvist LM, Lundman BM., Outcomes of diabetes care:a population-based study. Int J Qual Health Care 2003;15:301-7
40. Freemantle N, Evans M, Christensen T, et al. A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine:a meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:564-71
41. Jonasson JM, Ye W, Sparén P, et al. Risks of nontraumatic lower-extremity amputations in patients with type 1 diabetes:a population-based cohort study in Sweden. Diabetes Care 2008;31:1536-40
42. Jönsson L, Bolinder B, Lundkvist J., Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health 2006;9:193-8
43. Lauridsen JT, Lønborg J, Gundgaard J, Jensen HH., Diminishing marginal disutility of hypoglycaemic events:results from a time trade-off survey in five countries. Qual Life Res 2014;23:2645-50
44. Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes:an observational study. Lancet 2011;378:140-6
45. Wolowacz S, Pearson I, Shannon P, et al. Development and validation of a cost–utility model for type 1 diabetes mellitus. Diabet Med 2015;32:1023-35
46. Sørensen J, Ploug UJ. The Cost of Diabetes-Related Complications:Registry-Based Analysis of Days Absent from Work. Economics Research International 2013:Article ID 618039
47. TLV. Ändring i Läkemedelsförmånsnämndens allmänna råd (LFNAR 2003:2) om ekonomiska utvärderingar. Available at:http://www.tlv.se/Upload/Lagar_och_foreskrifter/TLVAR_2015_1.pdf last accessed 15 Nov 2016
48. Koopmanschap MA, Rutten FF., A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10:460-6
49. Henriksson M, Jindal R, Sternhufvud C, et al. A systematic review of cost-effectiveness models in type 1 diabetes mellitus. Pharmacoeconomics 2016;34:569-85